Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, TGen to Launch Genetic Tests in US

NEW YORK (GenomeWeb) — Australian diagnostics firm Genetic Technologies said today that it has signed a memorandum of understanding to commercialize its range of polygenic risk tests in the US with the Translational Genomics Research Institute.

Under the terms of the deal, the partners will work together on a US commercialization strategy for Genetic Technologies' existing polygenic risk tests — which include its BrevaGenplus breast cancer risk assessment test — and future tests for indications in oncology, cardiovascular disease, and diabetes.

Genetic Technologies and Phoenix, Arizona-based TGen will also establish a joint US-based CLIA laboratory to offer the tests and work together to raise the funding necessary to support their alliance.

Additional terms were not disclosed.

"We are excited to be working with such a prestigious organization as TGen in bringing our current and developing future polygenic risk tests to the US market," Genetic Technologies Chairman Paul Kasian said in a statement.

Last summer, Genetic Technologies partnered with Beijing Zishan Health Consultancy on the establishment of a joint venture to offer its tests in China.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.